Search
Eupraxia Pharmaceuticals Inc
EPRXAdd to Watchlist
6.690USD
-0.020-0.30%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
413.50MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated:Analyst Rating
Based on
9
analysts
Buy
Current Rating
16.444
Target Price
+145.07%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
562
Total
5
Median
6
Average
Company name
Ratings
Analysts
Eupraxia Pharmaceuticals Inc
EPRX
9
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
1
2
3
...
113
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Eupraxia Pharmaceuticals Inc's price target?
Analysts forecast that Eupraxia Pharmaceuticals Inc's price target is USD 12.00, with the highest forecast at USD 14.00 and the lowest forecast at USD 11.00.
How have Eupraxia Pharmaceuticals IncEPRX's recent earnings per share performed?
The market expectation was USD -0.22, while Eupraxia Pharmaceuticals IncEPRX's earnings per share (EPS) for the previous quarter was USD -0.33. EPS for the next quarter is expected at USD -0.25.
What is the analyst rating for Eupraxia Pharmaceuticals Inc?
Based on the ratings of Eupraxia Pharmaceuticals Inc's stock from 9 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.